Cantourage Group (HIGH) Company presentation summary

Investment profile

• Pan-European medical cannabis platform positioned for profitable growth in highly regulated markets, with an asset-light, capital-efficient model.

• Strong market positions in Germany, the UK and Poland; international markets contributed 54% of Q2 2026 revenue, up from 16%.

• Operates mainly in five countries and identifies France, Italy and Spain as promising markets for future growth.

Market opportunity and access

• Germany: 84m population, 17m potential patients and 500k medical cannabis patients; penetration of the addressable pool remains below 3%.

• UK: 69.5m population, 5m potential patients and 100k medical cannabis patients; private clinics treat nearly all patients.

• Poland: 37.5m population, 6–8m potential patients and 300k medical cannabis patients; the import-dependent market has returned to growth after tighter telemedicine rules.

• Across Germany, the UK and Poland, the presentation estimates 28m potential patients and 1.2m cannabis patients, with market penetration below 5%.

• Growth drivers include simplified prescribing in Germany, digital clinics in the UK, and unmet medical needs and broader product availability across markets.

Operating model and portfolio

• Sources from selected growers worldwide and connects them directly with pharmacies and patients, avoiding the large fixed investments of owned cultivation facilities.

• Can bring a legal cultivator into EU target markets within three to six months through grower certification, importing, manufacturing and distribution.

• Telemedicine platforms in Germany and the UK support online registration, medical consultations, prescriptions and pharmacy fulfilment.

• Product range includes dried flowers, cannabidiol and dronabinol APIs, distillates and extracts; a multi-brand strategy spans value to premium products.

• The gramz brand uses sales and telemedicine insights to launch sought-after products and offer curated products at attractive prices.